Mehmet Hakan Aksözen

Mehmet Hakan Aksözen

Auto-generated profile, based on publicly available information

Mehmet Hakan Aksözen

International Porphyria Patient Network, Hegarstrasse 3, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Energy and Buildings
Verified
Journal Article
Closed access
MAMehmet Aksoezen
Mehmet Aksoezen
MDMagdalena Daniel
Magdalena Daniel
UHUta Hassler
Uta Hassler
NKNiklaus Kohler
Niklaus Kohler

31 March 2016 in Building Research & Information
Verified
Journal Article
Closed access
MAMehmet Aksözen
Mehmet Aksözen
UHUta Hassler
Uta Hassler
NKNiklaus Kohler
Niklaus Kohler
What are the patterns and influences on the lifespan of the building stock? This paper presents (1) the reconstitution of an urban building stock composed of more than 60 000 buildings, (2) the analysis of the development of this stock over a period of 180 years (constructions and demolitions), and (3) the analysis of building mortality patterns and reasons for demolition resulting from historic decisions and regimes. A method to reconstitute the stock from different data sources is presented. The mortality models take into account not only the present demolition rates and the age distribution of the ‘survivors' but also the disappeared buildings. The main results are new insights into the lifespan behaviour of buildings according to their period of construction (cohorts) as well as the reasons for demolition. The demolitions do not show specific explanation patterns, but changing influences of the construction activities over time. The average demolition age of all buildings in Zurich, Switzerland, decreased from over 200 years to fewer than 70 years. A total of 18 000 buildings have been demolished over the 180-year period. The presented methods and results can be integrated in multidimensional geographical information systems (GIS) as comprehensive planning, scenario and regulatory tools.

31 March 2016 in Building Research & Information
Verified
Journal Article
Closed access
MAMehmet Aksözen
Mehmet Aksözen
UHUta Hassler
Uta Hassler
MRMathieu Rivallain
Mathieu Rivallain
NKNiklaus Kohler
Niklaus Kohler
Research is presented on the estimation of the lifespan of cohorts of buildings and building stocks. This is based on the analysis of extensive longitudinal data of the 55 000 buildings in the City of Zurich from 1832 and 2010. The survival probability from different perspectives considers age, construction periods, and demolition periods for both existing and demolished buildings. Survival probability is established using a Kaplan–Meier estimator. A more in-depth approach to the mortality of buildings is then determined by differentiating building age, use, size and geographical situation (district). The use of a common geographical information system (GIS) allows longitudinal building data to be linked to a geographical hierarchy of three levels of analysis (city, district and building) accounting for the different granularity on each level (neighbourhoods, quarters, building parts). A comparison of the two methods indicates that the choice of the observed time periods can lead to very different results. The analysis of the three levels shows the possibilities and limits of combined statistical and historical approaches. Mortality analysis is a promising approach to inform policy and practice; it could become a new link between long-term scenario planning, construction policies and institutional regimes.

Jasmin Barman-AksözenJasmin Barman-Aksözen
Jasmin Barman-Aksözen
AMAnna-Elisabeth Minder
Anna-Elisabeth Minder
FGFrancesca Granata
Francesca Granata
MPMårten Pettersson
Mårten Pettersson
CDCornelia Dechant
Cornelia Dechant
RFRocco Falchetto
Rocco Falchetto
Erythropoietic protoporphyria (EPP) is an ultra-rare inborn error of metabolism characterised by painful phototoxic burn injuries after short exposure times to visible light. Patients with EPP are highly adapted to their condition which makes the quantification of their health-related quality of life (QoL) challenging. In the presented patient-initiated feasibility study, we describe a new approach to assess treatment benefits in EPP by measuring QoL with the generic EQ-5D instrument in five patients under long-term (≥two years) treatment with afamelanotide, the first approved therapy for EPP. For the study, we selected patients with EPP who in addition were affected by an involuntary treatment interruption (caused by a temporary reimbursement suspension) because we hypothesized that individuals who had previously unlearned their adaptation are better able to assess their life without treatment than treatment-naïve patients. QoL under treatment was comparable to the age-matched population norm, and retrospective results for a treatment interruption and phototoxic reaction time point were comparable to the QoL of patients with chronic neuropathic pain and acute burn injuries, respectively. The results were accepted by the National Institute for Health and Care Excellence in England for their evaluation of the cost-effectiveness of afamelanotide, i.e., the calculation of quality-adjusted life years.

Jasmin Barman-AksözenJasmin Barman-Aksözen
Jasmin Barman-Aksözen
NHNicole Hentschel
Nicole Hentschel
MPMårten Pettersson
Mårten Pettersson
ESEva Schupp
Eva Schupp
FGFrancesca Granata
Francesca Granata
RFRocco Falchetto
Rocco Falchetto
The National Institute for Health and Care Excellence (NICE) in England uses quality-adjusted life years (QALYs) to assess the cost-effectiveness of treatments. A QALY is a measure that combines the size of the clinical benefit of a treatment with the time the patient benefits from it, i.e., the time horizon. We wanted to know how consistently QALY gains are calculated at NICE. Therefore, we have analysed information on the time horizons used for the QALY calculations of the concluded evaluations conducted under the Highly Specialised Technologies programme for treatments of very rare diseases at NICE. For treatments with final guidance published by December 2023 (n = 29), a time horizon of median 97.5 years (range: 35 to 125 years) was used to calculate the QALY gains. For most QALY calculations, the accepted time horizon was longer than either the expected treatment duration or the estimated life expectancy. In contrast, for the only technology with a final negative funding decision, i.e., afamelanotide for treating the lifelong chronic disease erythropoietic protoporphyria, a time horizon that was shorter than the expected treatment duration was used. The fairness and consistency of the evaluation process of treatments for very rare diseases at NICE should be reviewed.

4 May 2022 in Disability & Society
Verified
Journal Article
Open access
Jasmin Barman-AksözenJasmin Barman-Aksözen
Jasmin Barman-Aksözen
FGFrancesca Granata
Francesca Granata
MAMehmet Hakan Aksözen
Mehmet Hakan Aksözen
CDCornelia Dechant
Cornelia Dechant
RFRocco Falchetto
Rocco Falchetto
Erythropoietic protoporphyria (EPP) is an ultra-rare genetic disorder characterised by intolerance to visible light. Starting in early childhood, people with EPP suffer from social isolation, impaired educational and occupational opportunities, and low quality of life. Afamelanotide is the only effective and approved therapy for EPP. In England, its cost-effectiveness is currently assessed by the National Institute for Health and Care Excellence (NICE), which in 2018 issued a negative recommendation for funding. Stakeholder organisations, including our patient organisation, submitted appeals against the recommendation, which were upheld in all possible grounds. Moreover, the appeal panel expressed concerns about whether the evaluating committee discriminated against people with EPP and suggested that it seek guidance regarding the Equality Act 2010. However, three years later, the identified issues have not been addressed and patients in England remain without treatment. Afamelanotide represents another example for the trend towards a loss of fairness in NICE decisions.